Trial watch: Dendritic cell-based anticancer therapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10293139" target="_blank" >RIV/00064203:_____/14:10293139 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/14:10293139
Result on the web
<a href="http://dx.doi.org/10.4161/21624011.2014.963424" target="_blank" >http://dx.doi.org/10.4161/21624011.2014.963424</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4161/21624011.2014.963424" target="_blank" >10.4161/21624011.2014.963424</a>
Alternative languages
Result language
angličtina
Original language name
Trial watch: Dendritic cell-based anticancer therapy
Original language description
The use of patient-derived dendritic cells (DCs) as a means to elicit therapeutically relevant immune responses in cancer patients has been extensively investigated throughout the past decade. In this context, DCs are generally expanded, exposed to autologous tumor cell lysates or loaded with specific tumor-associated antigens (TAAs), and then reintroduced into patients, often in combination with one or more immunostimulatory agents. As an alternative, TAAs are targeted to DCs in vivo by means of monoclonal antibodies, carbohydrate moieties or viral vectors specific for DC receptors. All these approaches have been shown to (re) activate tumor-specific immune responses in mice, often mediating robust therapeutic effects. In 2010, the first DC-based preparation (sipuleucel-T, also known as Provenge((R))) has been approved by the US Food and Drug Administration (FDA) for use in humans. Reflecting the central position occupied by DCs in the regulation of immunological tolerance and adaptiv
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EC - Immunology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
OncoImmunology
ISSN
2162-4011
e-ISSN
—
Volume of the periodical
3
Issue of the periodical within the volume
11
Country of publishing house
US - UNITED STATES
Number of pages
16
Pages from-to
—
UT code for WoS article
000346923100008
EID of the result in the Scopus database
—